Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B‐cell lymphoma, leg type

Autor: Béatrice Crickx, Vincent Descamps, Julie Di-Lucca, Flore Sicre de Fontbrune, Eduardo Marinho, Lydia Deschamps, Mahdi Al Dhafiri
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Zdroj: Clinical Case Reports
Clinical case reports, vol. 7, no. 5, pp. 964-967
ISSN: 2050-0904
Popis: Primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL‐LT) is one of the major four subtypes of cutaneous B‐cell lymphoma 1 and characterized by its aggressive nature, poor prognosis, and occurrence in advanced age, with five‐years survival estimations of approximately 50%‐60%. 2, 3 Clinically it is represented as red to purple nodules that arise mainly in the lower extremities. Histologically it is characterized by the presence of confluent sheets of large cells with round nuclei, with strong expression of Bcl‐2, as well as intermediate or positive staining for MUM‐1 protein.1, 4, 5 The initial treatment is based on rituximab associated with polychemotherapy,2, 3, 6 with no ideal therapy for relapsing or refractory forms. To date, there are two previously reported cases showing a promising effect of lenalidomide in relapsed cases,6, 7 with one recent phase II study on the efficacy of lenalidomide in relapsing or refractory PCDLBCL‐LT.4 Herein, we exhibit a case successfully treated with lenalidomide (Revlimid®) in second‐line treatment.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje